Cosa sono i Prebiotici e a cosa servono

I PREBIOTICI sono sostanze di origine alimentare non digeribili, che possono promuovere selettivamente la crescita e/o attività di uno o più batteri già presenti nel tratto intestinale o assunti contestualmente al probiotico.

L’equilibrio del microbiota intestinale viene favorito, quindi, anche dall’assunzione con la dieta dei prebiotici.

L’interesse per i prebiotici nacque in seguito alle prime scoperte sui loro effetti benefici, per cui si cercò il modo per favorirne la crescita e l’attività.

Come abbiamo già visto per i probiotici, anche i prebiotici devono avere certe proprietà per essere definiti tali:

  • devono superare, pressoché indenni, i processi digestivi che avvengono nel primo tratto del tubo digerente (bocca, stomaco e intestino tenue);
  • devono rappresentare un substrato nutritivo fermentabile per la microflora intestinale, in modo da stimolare selettivamente la crescita e/o il metabolismo di una o di alcune specie batteriche ;
  • devono modificare positivamente la flora microbica a favore di quella simbionte (bifidobatteri, lattobacilli);
  • devono indurre effetti sul lume intestinale o a livello sistemico positivi per la salute umana.

Sono presenti in molti integratori di fermenti lattici, ma anche in diversi cibi, in particolar modo nella farina di frumento, nelle banane, nel miele, nel germe di grano, nell’aglio, nella cipolla, nei fagioli e nei porri.

I prebiotici più conosciuti e studiati sono gli oligosaccaridi ed in modo particolare i Frutto-oligosaccaridi (FOS) e l’ Inulina

Alcuni studiosi fanno rientrare nella categoria dei prebiotici anche altre sostanze, come i Galatto-oligo-saccaridi (TOS), i Gluco-oligo-saccaridi (GOS) ed i Soia-oligo-saccaridi (SOS).

Effetti dei prebiotici sulla salute umana

La loro importanza è collegata agli effetti benefici che svolgono per il nostro organismo.

Vediamo i principali:

  • Diminuzione del pH fecale con acidificazione del contenuto intestinale

La fermentazione di prebiotici ad opera della microflora intestinale crea condizioni ambientali favorevoli per la crescita dei simbionti (Bifidobatteri, Lactobacillus Acidophilus) ed ostili per lo sviluppo di microrganismi patogeni

Agli acidi grassi a corta catena prodotti dalla fermentazione dei prebiotici vengono attribuite anche funzioni protettive contro le malattie infiammatorie intestinali

  • Integrità della mucosa e proliferazione cellulare 

Gli acidi grassi a corta catena (in special modo il butirrico), oltre a ridurre la proliferazione di patogeni e ad avere proprietà antiputrefattive, sono un valido nutrimento per le cellule della mucosa del colon e contribuiscono a migliorarne trofismo ed efficacia

Tutto ciò si traduce in un ottimo assorbimento delle sostanze nutritive, a discapito di quelle tossiche.

  • Aumento della biodisponibilità di minerali 

I prebiotici facilitano indirettamente l’assorbimento di acqua e di alcuni minerali in forma ionizzata, in particolare Calcio e Magnesio.

  • Azione ipocolesterolemizzante

In alcuni studi i prebiotici si sono dimostrati utili nel ridurre la concentrazione plasmatica di colesterolo e, in misura minore, di trigliceridi.

A questo punto, se stai cercando delle soluzioni per migliorare il benessere del tuo corpo, appare evidente quanto sia importante seguire dei corretti regimi alimentari,ma non solo.

Quando necessario è utile assumere un integratore specifico, contenente non solo batteri vivi, ma anche prebiotici. 

Queste sostanze sono, infatti, fondamentali per la salute dell’intestino e possono aiutare a regolare anche il sistema immunitario. 

Un’ottima soluzione per integrare correttamente i prebiotici e probiotici necessari al benessere intestinale è rappresentata dal MASUROTA®

Frutto della ricerca Deltha Pharma, in collaborazione con l’Università Cattolica del Sacro Cuore e Policlinico Agostino Gemelli di Roma, il MASUROTA® è un integratore alimentare a base di prebiotici attentamente selezionati, potenziati dal prebiotico INULINA.

Disponibile in due formulazioni, entrambe ad alto dosaggio (25 miliardi di cellule vive e 50 miliardi di cellule vive), il MASUROTA® favorisce il corretto equilibrio della flora batterica intestinale e supporta il suo naturale ripristino in caso di squilibri e disbiosi.

La composizione relativa ai ceppi utilizzati è unica sul mercato e lo dimostra il brevetto attualmente depositato presso l’Università Cattolica del Sacro Cuore.

Scopri di più sul MASUROTA®

Bibliografia

  1. AAVV, Probiotici e Salute. Stato dell’Arte basato sulle evidenze, in Pacini Editore, 2010
  2. Allen SJ et al. Dietary supplementation with lactobacilli and bifidobacteria is well tolerated and not associated with adverse events during late pregnancy and early infancy. J Nutr 2010;140(3):483-8, DOI:10.3945/jn.109.117093, PMID 20089774
  3. An HM et al. Efficacy of Lactic Acid Bacteria (LAB) supplement in management of constipation among nursing home residents. Nutr J 2010;9:5, DOI:10.1186/1475-2891-9-5, PMC PMC2835640, PMID 20137076.
  4. Aronsson L et al. Decreased fat storage by Lactobacillus paracasei is associated with increased levels of angiopoietin-like 4 protein (ANGPTL4). PLoS One2010;5(9). DOI:10.1371/journal.pone.0013087, PMID 20927337
  5. Bakken JS. Staggered and tapered antibiotic withdrawal with administration of kefir for recurrent Clostridium difficile infection. Clin Infect 25 Dis. 2014 Sep 15;59(6):858-61.
  6. Beausoleil M et al. Effect of a fermented milk combining Lactobacillus acidophilus Cl1285 and Lactobacillus casei in the prevention of antibiotic-associated diarrhea: a randomized, double-blind, placebo-controlled trial. Canadian Journal of Gastroenterology 2007;21(11):732–6.
  7. Besselink MG et al. Probiotic prophylaxis in predicted severe acute pancreatitis: a randomised, double-blind, placebo-controlled trial. Lancet 2008;371(9613):651–9, DOI:10.1016/S0140-6736(08)60207-X
  8. Bosscher D et al. Food-based strategies to modulate the composition of the intestinal microbiota and their associated health effects. J Physiol Pharmacol 2009;60 Suppl 6:5-11, PMID 20224145.
  9. Bottazzi V. Latte-fermentati funzionali probiotici. Edizioni scientifiche 2004:pag 53
  10. Boyle RJ, Bath-Hextall FJ, Leonardi-Bee J, Murrell DF, Tang ML. Probiotics for treating eczema. Cochrane Database Syst Rev 2008;4:CD006135, DOI:10.1002/14651858.CD006135.pub2
  11. Braat H et al. Lactobacillus rhamnosus induces peripheral hyporesponsiveness in stimulated CD4+ T cells via modulation of dendritic cell function. The American journal of clinical nutrition2004;80(6):1618–25, PMID 15585777.
  12. Brady LJ et al. The role of probiotic cultures in the prevention of colon cancer. The Journal of Nutrition 2000;130(2S Suppl):410S–414S, PMID 10721916.
  13. BussarinK & Rakshit SK. Microbial and processing criteria for production of probiotics: a review. Food techol biotechnol 2006;44(3):371-9.
  14. Cammarota G, Masucci L. et al. Randomised clinical trial: faecal microbiota transplantation by colonoscopy vs. vancomycin for the treatment of recurrent Clostridium difficile infection. Aliment Pharmacol Ther. 2015 May;41(9):835-43.
  15. Canganella F et al. A microbiological investigation on probiotic preparations used for animal feeding. Microbiol Res 1996;151:167-75.
  16. Chen C et al. Probiotics have clinical, microbiologic and immunologic efficacy in acute infectious diarrhea. The pediatric infectious dis J 2010;29(2):135-8.
  17. Claes IJJ et al. Genetic and Biochemical Characterization of the Cell Wall Hydrolase Activity of the Major Secreted Protein of Lactobacillus rhamnosus GG. PLosONE 2012;7(2):e31588
  18. Cremonini F, Di Caro S, Nista EC, et al., Meta-analysis: the effect of probiotic administration on antibiotic-associated diarrhoea. Aliment. Pharmacol. Ther. 2002;16(8):1461-7; DOI:10.1046/j.1365-2036.2002.01318.x, PMID 12182746.
  19. Cui Y et al. New advances in exoplysaccharides production of Streptococcus thermphilus. Arch Microbioll 2017;199:799-809.
  20. Cutting SM. Bacillus probiotics. Food microbiol 2011;28:214-20.
  21. Daniells S .Probiotics may protect against food poisoning. Nutraingredients.com, 20 marzo 2007.
  22. Davis CD, Milner GA. Gastrointestinal microflora, food components and colon cancer prevention. J Nutr Biochem 2009;20(10):743-52, DOI:10.1016/j.jnutbio.2009.06.001.
  23. De Hoon MJL et al. Hierarchical evolution of the bacterial sporulation network. Curr Biol . 2010;20(17): R735–R745. doi:10.1016/j.cub.2010.06.031.
  24. Debast et al. European Society of Clinical Microbiology and Infectious Diseases: Update of the Treatment Guidance Document for Clostridium difficile Infection -Clin Microbil and Infect 2014;20(2)
  25. Di Gioia D et al. Bifidobacteria: their impact on gut microbiota composition and their applications as probiotics in infants Appl Microbiol Biotechnol (2014) 98:563–577
  26. Doron SI et al. Probiotics for prevention of antibiotic-associated diarrhea. J Clin Gastroenterol2008;42:S58-63, DOI:10.1097/MCG.0b013e3181618ab7
  27. D’Souza AL et al. Probiotics in prevention of antibiotic associated diarrhoea: meta-analysis. BMJ 2002;324(7350):1361, DOI:10.1136/bmj.324.7350.1361
  28. Famularo G et al. Microecology, bacterial vaginosis and probiotics: perspectives for bacteriotherapy. Med. Hypotheses 2001;56(4):421–30, DOI:10.1054/mehy.2000.1195.
  29. Famularo G et al. Probiotic lactobacilli: an innovative tool to correct the malabsorption syndrome of vegetarians? Med. Hypotheses 2005;65(6):1132–5, DOI:10.1016/j.mehy.2004.09.030, PMID 16095846.
  30. Fiormonti J et al. Probiotics: what are they? What are their effects on gut physiology? Best Practice& Res Clin Gastroenter 2003;17(5):711-24.
  31. Gotteland M et al. Systematic review: are probiotics useful in controlling gastric colonization by Helicobacter pylori? Aliment Pharmacol Ther 2006;23(8):1077-86, DOI:10.1111/j.1365-2036.2006.02868.x.
  32. Gratz SW et al. Probiotics and gut health: a special focus on liver diseases. World J Gastroenterol 2010;16(4):403-10, PMID 20101763.
  33. Hamilton-Miller JM. The role of probiotics in the treatment and prevention of Helicobacter pylori infection. International Journal of Antimicrobial Agents 2003;22(4):360–6, DOI:10.1016/S0924-8579(03)00153-5.
  34. Hatakka K et al. Effect of long term consumption of probiotic milk on infections in children attending day care centres: double blind, randomised trial. BMJ 2001;322(7298):1327, DOI:10.1136/bmj.322.7298.1327, PMC 32161
  35. Head KA. Natural approaches to prevention and treatment of infections of the lower urinary tract. Altern Med Rev 2008;1(3):227-44, PMID 18950249.
  36. Hickson M et al. Use of probiotic Lactobacillus preparation to prevent diarrhea associated with antibiotics: randomised double blind placebo controlled trial. BMJ 2007;335(7610):80, DOI:10.1136/bmj.39231.599815.55, PMC 1914504
  37. Huang JMet al. Immunostimulatory activity of Bacillus spores. FEMS Immunol Med Microbiol 2008;53:195-203.
  38. Indrio F et al. Effects of probiotic and prebiotic on gastrointestinal motility in newborns. J Physiol Pharmacol 2009;60(Suppl 6):27-31, PMID 20224148
  39. Kondo S et al. Antiobesity effects of Bifidobacterium breve strain B-3 supplementation in a mouse model with high-fat diet-induced obesity. Biosci Biotechnol Biochem 2010;74(8):1656-61, PMID 20699581.
  40. La Ragione RM et al. Bacillus subtilis spores competitively exclude Escherichia coli O78:K80 in poultry. Vet Microbiol 2001;79:133-42.
  41. La Ragione RM & Woodward M. competitive exclusion by Bacillus subtilis spores of Salmonella enterica seotype Enteritidis and Clostridium perfringens in young chicken. Vet Microbiol 2003;94:245-56.
  42. Lamiki P et al. Probiotics in diverticular disease of the colon: an open label study. J Gastrointestin Liver Dis 2010;19(1):31-6, PMID 20361072.
  43. Lau CS, Chamberlain RS. Probiotics are effective at preventing Clostridium difficile-associated diarrhea: a systematic review and meta-analysis. Int J Gen Med. 2016 Feb 22;9:27-37.
  44. Lesbros-PantoflickovaD et al. Helicobacter pylori and probiotics. J Nutr 2007;137(3 Suppl 2):812S-8S, PMID 17311980.
  45. Li M et al. Fecal microbiota transplantation and bacterial consortium transplantation have comparable effects on the re-establishment of mucosal barrier function in mice with intestinal dysbiosis. Front Microbiol. 2015 Jul 7;6:692.
  46. Marcos A et al, Yogurt cultures plus Lactobacillus casei DN-114 001may act as an Immunomodulator agent. Eur J Nutr 2004.
  47. Marteau P. The clinical importance of intestinal microbiota. Gastroenterol Clin Biol 2010;34(Suppl 1):S93-7, DOI:10.1016/S0399-8320(10)70026-9.
  48. Maziade PJ et al. Impact of adding prophylactic probiotics to a bundle of standard preventative measures for Clostridium difficile infections: enhanced and sustained decrease in the incidence and severity of infection at a community hospital. Curr Med Res and Opinion 2013;29(10):1341-1347, DOI:10.1185/03007995.2013.833501
  49. Maziade PJ et al. A Decade of Experience in Primary Prevention of Clostridium difficile Infection at a Community Hospital Using the Probiotic Combination Lactobacillus acidophilus CL1285, Lactobacillus casei LBC80R, and Lactobacillus rhamnosus CLR2 (Bio-K+). CID 2015:60 (Suppl 2):S144-47.
  50. Mcfarland LV., Meta-analysis of probiotics for the prevention of antibiotic associated diarrhea and the treatment of Clostridium difficile disease Am J Gastroenterol 2006;101(4):812-22; DOI:10.1111/j.1572-0241.2006.00465.x,
  51. McMillan. Disruption of urogenital biofilms by lactobacilli., in Colloids Surf B Biointerfaces 2011; DOI:10.1016/j.colsurfb.2011.03.016, PMID 21497071Näse L et al. Effect of long-term consumption of a probiotic bacterium, Lactobacillus rhamnosus GG, in milk on dental caries and caries risk in children. Caries Research 2001;358(6):412–20, DOI:10.1159/000047484
  52. Ouwehand AC et al. Probiotics: an overview of beneficial effects, in Antonie Van Leeuwenhoek, vol. 82, 1-4, agosto 2002, pp. 279-89, DOI:10.1023/A:1020620607611
  53. Peta Bee, Probiotics, Not so friendly after all, in The Times (London), 10 novembre 2008.
  54. Petrof et al. Stool substitute transplant therapy for the eradication of Clostridium difficile infection. Microbiome. Jan 9;1(1):3.
  55. Pitsouni E et al. Does the use of probiotics/synbiotics prevent postoperative infections in patients undergoing abdominal surgery? A meta-analysis of randomized controlled trials. Eur J Clin Pharmacol 2009;65(6):561-70, DOI:10.1007/s00228-009-0642-7, PMID 19326107.
  56. Putignani L et al. The human gut microbiota: a dynamic interplay with the host from birth to senescence settled during childhood. Pediatric Res 2014;76:1-10
  57. Rastmanesh R. High polyphenol, low probiotic diet for weight loss because of intestinal microbiota interaction. Chem Biol Interact 2011;189(1-2):1-8, DOI:10.1016/j.cbi.2010.10.002.
  58. Reid G. Probiotic agents to protect the urogenital tract against infection. Am. J. Clin. Nutr. 2001;73(2 Suppl):437S–443S, PMID 11157354.
  59. Reid G et al. Potential uses of probiotics in clinical practice. Clin. Microbiol. Rev 2003;16(4):658–72, DOI:10.1128/CMR.16.4.658672.2003
  60. Quigley EM. The enteric microbiota in the pathogenesis and management of constipation. Best Pract Res Clin Gastroenterol 2011;25(1):119-26, DOI:10.1016/j.bpg.2011.01.003.
  61. Saggioro A. Probiotics in the Treatment of Irritable Bowel Syndrome. Journal of Clinical Gastroenterology 2004;38:S104-S106
  62. Sanders ML. Probiotics: definition,source, selection and uses. CID 2008;46(Suppl 2):S58-61
  63. Sazawal S, Hiremath G, Dhingra U, Malik P, Deb S, Black RE., Efficacy of probiotics in prevention of acute diarrhoea: a meta-analysis of masked, randomised, placebo-controlled trials, in Lancet Infect Dis 2006;6(6):374–82, DOI:10.1016/S1473-3099(06)70495-9.
  64. Sellars, R.L., in “Acidophilus Products (Therapeutic Properties of Fermented Milks)”, Chapman & Hall, London 2007:81–116.
  65. Spinler JK, Ross CL, Savidge TC. Probiotics as adjunctive therapy for preventing Clostridium difficile infection – What are we waiting for? Anaerobe. 2016 Oct;41:51-57. doi: 10.1016/j.anaerobe.2016.05.007.)
  66. Surawicz CM., Role of probiotics in antibiotic-associated diarrhea, Clostridium difficile-associated diarrhea, and recurrent Clostridium difficile-associated diarrhea. J Clin Gastroenterol 2008;42: S64–70, DOI:10.1097/MCG.0b013e3181646d09.
  67. Surawicz CM et al. Guidelines for diagnosis, treatment and prevention of Clostridium difficile infections. Am J Gastroenterol 2013;108:478–498; doi: 10.1038/ajg.2013.4;
  68. Szajewska H, Mrukowicz J., Meta-analysis: non-pathogenic yeast Saccharomyces boulardii in the prevention of antibiotic-associated diarrhoea. Aliment Pharmacol Ther 2005;22(5):365–72, DOI:10.1111/j.1365-2036.2005.02624.x
  69. Szajewska H, Ruszczyński M, Radzikowski A., Probiotics in the prevention of antibiotic-associated diarrhea in children: a meta-analysis of randomized controlled trials. J Pediatr 2006;149(3):367–372, DOI:10.1016/j.jpeds.2006.04.053
  70. Szajewska H et al. Use of probiotics for management of acute gastroenteritis: a position paper by the ESPGHAN Working Group for Probiotics and Prebiotics. J. Pediatr. Gastroenterol. Nutr 2014;58(4):531-9, DOI:10.1097/MPG.0000000000000320
  71. Tabbers MM et al. Is Bifidobacterium breve effective in the treatment of childhood constipation? Results from a pilot study. Nutr J 2011;10:19, DOI:10.1186/1475-28911019, PMC PMC3048518, PMID 21345213
  72. Thakur K et al. Lactic acid bacteria as a cell factory for riboflavin production. Microbial biotechol 2016;9(4):441-51.
  73. Timmermann HM et al. Monostrain, multistrain and multispecies probiotics- a comparison of functionality and efficacy. Int J Food Microbiol 2004;96:219-33.
  74. Tong JL et al. Meta-analysis: the effect of supplementation with probiotics on eradication rates and adverse events during Helicobacter pylori eradication therapy. Aliment Pharmacol Ther 2007;25(2):155-68, DOI:10.1111/j.1365-2036.2006.03179.x.
  75. University of Pennsylvania School of Medicine, ‘Good’ bacteria keep immune system primed to fight future infections, in Science Daily 2010.
  76. Viljanen M et al. Induction of inflammation as a possible mechanism of probiotic effect in atopic eczema-dermatitis syndrome. J Allergy Clin Immunol 2005;115:1254-9, PMID 15940143.
  77. Wollowski I, Rechkemmer G, Pool-Zobel BL. Protective role of probiotics and prebiotics in colon cancer. The American Journal of Clinical Nutrition 2001;73(2):451S–455S, PMID 11157356.
  78. World Gastroenterology Organisation Practice Guideline – Probiotics and prebiotics, in worldgastroenterology.org (archiviato dall’url originale il 20 febbraio 2011).
  79. Yaşar B et al. Efficacy of probiotics in Helicobacter pylori eradication therapy. Turk J Gastroenterol 2010;21(3):212-7, PMID 20931422.
  80. Ye X et al. Bacillus subtilis inhibition of enterotoxic Escherichia coli-induced activation of MAPK signaling pathways in Caco-2 cells. Ann Microbiol (2013) 63:577–581
  81. Zaharoni H et al. Probiotics improve bowel movements in hospitalized elderly patients-the PROAGE study. J Nutr Health Aging 2011;15(3):215-20, PMID 21369670.
  82. Ziemniak W et al. Helicobacter pylori eradication taking into account its resistance to antibiotics. J Physiol Pharmacol 2006;57(Suppl 3):123-41, PMID 17033111.
  83. Zhou C et al. Lactobacilli inhibit interleukin-8 production induced by Helicobacter pylori lipopolysaccharide-activated Toll-like receptor 4. World J Gastroenterol 2008;14(32): 5090-5, PMID 18763295.